English 
简体中文 Rufinamide (RUF)
1) The main possible mechanism: prolongation of the inactive state of sodium channels.
2) Therapeutic indications: adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older.
3) Warning: Other types of epilepsy syndromes are less commonly used. In addition, because this drug can cause a shortening of the QT interval, patients with familial short QT syndrome should not use it.
4) Dosage for children: Click to view the dosage for children of different ages and weights.
5) Major adverse reactions in children: Headache, dizziness, fatigue, drowsiness, nausea, and allergies may occur, and some may cause severe status epilepticus.
6) Interaction with other anti-epileptic drugs: Valproate sodium will significantly increase the plasma concentration of rufinamide (especially in patients weighing less than 30kg). Carbamazepine, phenobarbital, primidone, phenytoin, and vigabatrin will reduce the blood concentration of rufinamide. Rufinamide can increase the plasma concentrations of phenytoin and phenobarbital. Rufinamide can reduce the concentrations of carbamazepine and lamotrigine.
7) Interaction with non-anti-epileptic drugs: Interacts with some hormonal contraceptives.